Adheron Therapeutics
Adheron Therapeutics is a privately held, Berkeley-based biotechnology company founded in 2003 that develops cell adhesion-disrupting technology to treat disease. It operates with 1-10 employees and no publicly disclosed products, revenue, or active investor base.
- Company typePrivate
- Founded2003
- HeadquartersBerkeley, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Adheron Therapeutics firmographics
Firmographics- Name
- Adheron Therapeutics
- Website
- https://adherontherapeutics.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Adheron Therapeutics is a privately held, Berkeley-based biotechnology company founded in 2003 that develops cell adhesion-disrupting technology to treat disease. It operates with 1-10 employees and no publicly disclosed products, revenue, or active investor base.
- Ownership category
- akta.pro rank
Adheron Therapeutics industry classification
Industry- Product category
- Biotechnology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Adheron Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Berkeley
- HQ country
- United States
- HQ region
- North America
Markets served
Adheron Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Adheron Therapeutics product offering
Product offeringCore offering
Adheron Therapeutics is a biotechnology company developing therapeutics that leverage proprietary cell adhesion disruption technology to treat a variety of diseases. Its core focus is applying pioneering biological approaches that interfere with cell adhesion mechanisms as a basis for novel therapeutic candidates. The company is research-stage and operates at small scale from Berkeley, California.
Differentiator
Problem solved
Functional benefit
Companies that use Adheron Therapeutics
Customer profileIdeal customer profiles1 record
Adheron Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Adheron Therapeutics competitors and assessment
Company assessmentEmerging players
- OncoMed Pharmaceuticals: OncoMed developed antibody therapeutics targeting cancer stem cell pathways, including several cell-surface receptors. Comparable as a small-cap antibody biotech focused on novel cell-surface mechanisms in oncology, with eventual acquisition by Mereo.
- Compass Therapeutics: Compass Therapeutics is a clinical-stage biotech developing antibody-based therapeutics for oncology, including bispecifics. Comparable as a small-cap antibody platform company working on novel immuno-oncology mechanisms.
- Mereo BioPharma: Mereo BioPharma acquires and develops novel biologics and small molecules for rare diseases and oncology, often in-licensing assets from larger pharma. Comparable as a small-cap platform that monetizes novel mechanism-based therapeutics through partnerships.
- Sutro Biopharma: Sutro is a clinical-stage biotech developing protein therapeutics, including antibody-drug conjugates and bispecifics, using a cell-free protein synthesis platform. Comparable as a platform-based protein therapeutics developer, though more advanced and with broader modality coverage.
Broad incumbents
- Genentech (Roche): Genentech is a major biopharma with significant work in antibody therapeutics and cell-surface targets across oncology and immunology. Relevant as a large incumbent that historically has both partnered with and acquired smaller biologics platforms, including in the cell adhesion space.
- argenx: argenx is a commercial-stage biotech that develops antibody therapeutics (e.g., FcRn antagonists) for autoimmune diseases. Comparable as a successful antibody therapeutics company that began as a small platform player, illustrating the potential trajectory for Adheron's adhesion-targeting platform.
- Pfizer: Pfizer has historically partnered with Adheron Therapeutics on cadherin-11 antibody programs. Relevant as a strategic incumbent with biologics capabilities and a history of in-licensing or partnering small-cap protein therapeutic platforms.
- MacroGenics: MacroGenics develops antibody-based therapeutics for cancer, including molecules that disrupt cell-surface protein interactions. Comparable as a more established antibody/biologics platform company working on similar mechanistic themes (cell-surface receptor targeting).
Direct peers
- Five Prime Therapeutics: Five Prime was a clinical-stage biotech developing protein therapeutics, including antibody-based therapies, against novel targets in cancer and immunology. Comparable to Adheron as a small-cap protein therapeutics platform targeting cell-surface biology.
- Adherex Technologies: Adherex Technologies was a clinical-stage biotech that developed therapeutics targeting N-cadherin and other cell adhesion molecules for oncology. It is the most direct historical comparable to Adheron Therapeutics given the shared cadherin / cell adhesion therapeutic focus.
Market position
Customer concentration
Adheron Therapeutics social profiles
Digital presenceAdheron Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adheron Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Adheron Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adheron Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adheron Therapeutics
What does Adheron Therapeutics do?
Adheron Therapeutics is a biotechnology company developing therapeutics that leverage proprietary cell adhesion disruption technology to treat a variety of diseases. Its core focus is applying pioneering biological approaches that interfere with cell adhesion mechanisms as a basis for novel therapeutic candidates. The company is research-stage and operates at small scale from Berkeley, California.
When was Adheron Therapeutics founded?
Adheron Therapeutics was founded in 2003. It employs 1 to 10 people.
Where is Adheron Therapeutics based?
Adheron Therapeutics is headquartered in Berkeley, United States, in the North America region.
Who are Adheron Therapeutics's main competitors?
Emerging players on record are OncoMed Pharmaceuticals, Compass Therapeutics, Mereo BioPharma and Sutro Biopharma. Broad incumbents are Genentech (Roche), argenx, Pfizer and MacroGenics. Direct peers are Five Prime Therapeutics and Adherex Technologies.
Does Adheron Therapeutics have an API?
No public API is recorded for Adheron Therapeutics.
What industry is Adheron Therapeutics in?
Adheron Therapeutics's product category is Biotechnology Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.